The new class of the human ASK1 inhibitors has been identified by Otava's scientists
March, 2011
Apoptosis signal-regulating kinase 1 (ASK1) has recently emerged as an attractive therapeutic target for the treatment of cardiac and neurodegenerative disorders. The selective inhibitors of ASK1 may become important compounds for the development of clinical agents. We have identified the ASK1 inhibitor among 3H-naphtho[1,2,3-de]quinoline-2,7-diones using receptor-based virtual screening. In vitro kinase assay revealed that ethyl 2,7-dioxo-2,7-dihydro-3H-naphtho[1,2,3-de]quinoline-1-carboxylate (NQDI-1) inhibited ASK1 with a Ki of 500 nM. The competitive character of inhibition is demonstrated in Lineweaver-Burk plots. In our preliminary selectivity study this compound exhibited strong specific inhibitory activity towards ASK1.
|
|
Read more...
|
|
The new class of potent ATP-competitive inhibitors of the human protein kinase CK2 has been identified
February, 2011
A novel series of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids has been synthesized and tested in vitro towards human protein kinase CK2.
|
|
Read more...
|
|
VI International Conference on Protein Kinase CK2
September 2010
Scientists from Otava, Ltd. participated in the VI International Conference on Protein Kinase CK2 (07-10 September, 2010, Cologne, Germany). Their oral presentation was addressed on the CK2 inhibitors development. |
|
III International Symposium Methods and Applications of Computational Chemistry
July, 2009
Scientists from Otava, Ltd. has attended the ІІІ International Symposium Methods and Applications of Computational Chemistry (June 28 - July 2, 2009, Odessa, Ukraine). At the Conference they gave a talk on “Computer-aided design of novel protein kinase CK2 inhibitors”. |
In September 2006 OTAVA opened North American office in Toronto, Canada
August, 2006
|
|
Read more...
|
In September 2006 OTAVA opened North American office in Toronto, Canada
August, 2006
|
|
Read more...
|
Otava and Life Chemicals Inc present the new cAMP Dependent Protein Kinase (PKA) focused library with 1998 compounds
April, 2006
This library has been created as a part of a joint project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project, Life Chemicals provides its Collection of 300 000 compounds and subsequent chemical optimization. Otava provides its drug-like Green Collection (50 000 compounds) and also is responsible for molecular modeling tasks.
|
|
Read more...
|
Otava and Life Chemicals Inc present the new human Phosphatidylinositol 3-Kinase (PI3K) focused library with 2189 compounds June, 2006
This library has been created as a part of a joint project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project, Life Chemicals provides its Collection of 300 000 compounds and subsequent chemical optimization. Otava provides its drug-like Green Collection (50 000 compounds) and also is responsible for molecular modeling tasks.
|
|
Read more...
|
New 2-sulfonyl-2-hetaryl-ethylaminesApril, 2006
2-Arylethylamines is a wide valuable family of biologically active compounds. Recently we have developed the synthesis of novel 2-arylsylfonyl-2-hetarylethylamines of general formula:
|
|
Read more...
|
Otava and Life Chemicals Inc present the new human Fibroblast Growth Factor Receptor 1 Tyrosine Kinase (FGFR1K) focused library with 1901 compounds
February, 2006
This library has been created as a part of a joint project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project, Life Chemicals provides its Collection of 300 000 compounds and subsequent chemical optimization. Otava provides its drug-like Green Collection (50 000 compounds) and also is responsible for molecular modeling tasks.
|
|
Read more...
|
Otava and Life Chemicals Inc present the new human Janus Kinase 2 (Jak2) focused library with 2325 compounds Jujy, 2006
This library has been created as a part of a joint project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project, Life Chemicals provides its Collection of 300 000 compounds and subsequent chemical optimization. Otava provides its drug-like Green Collection (50 000 compounds) and also is responsible for molecular modeling tasks.
|
|
Read more...
|
Otava and Life Chemicals Inc present the new Aurora B Kinase focused library with 2144 compounds September, 2006
This library has been created as a part of a joint project aimed at design of a large set of receptor-based sharp-focused libraries. In the framework of this project, Life Chemicals provides its Collection of 300 000 compounds and subsequent chemical optimization. Otava provides its drug-like Green Collection (50 000 compounds) and also is responsible for molecular modeling tasks.
|
|
Read more...
|
OTAVA Ltd. and ADAMED Sp. Z o.o. Announce Drug Discovery Collaboration January, 2007
Kyiv, 25th of October 2006 – OTAVA Ltd., a leading Ukrainian company that specializes in drug discovery technologies, and ADAMED Sp. Z o.o., Poland, have announced plans for an integrated drug discovery project focused on a kinase target.
|
|
Read more...
|
OTAVA Releases its Searchable Online Catalog using the eMolecules Hosted Catalog Service May, 2007
DEL MAR, California and TORONTO, Canada, April 17, 2007 – eMolecules, Inc., the provider of the world’s largest online chemistry database, and OTAVA Ltd., a leading Ukrainian company specializing in drug discovery technologies, announce the commercial availability of OTAVA’s new structure-searchable online chemical catalogs at http://otava.emolecules.com.
|
|
Read more...
|
OTAVA Ltd. and Institute of Genetics and Molecular Medicine at University of Edinburgh Announce Research Collaboration
February, 2008
Kyiv, 29 th of February 2008 – OTAVA Ltd., a leading Ukrainian company that specializes in drug discovery technologies, and Institute of Genetics and Molecular Medicine at University of Edinburgh, Cancer Research UK-p53 Signal Transduction Laboratories (UK), have announced plans for an integrated research project focused on a kinase targets.
|
|
Read more...
|
OTAVA sponsoring Protein Kinase Targets Conference
March, 2008
March 2008 – OTAVA Ltd. will sponsor Protein Kinase Targets Conference which will be held on June 23-25, 2008, Boston, MA. |
|
Read more...
|
OTAVA sponsoring Cambridge Healthtech Institute's Sixth Annual Discovery On Target Conference
July, 2008
July 2008 – OTAVA Ltd. will sponsor Discovery on Target Conference which will be held on October 20-23, 2008, World Trade Center, Boston. |
|
Read more...
|
OTAVA Ltd. and SIGMA-ALDRICH Sign Agreement to Jointly Develop Novel Fluorescent Stain NANCY-520 for dsDNA Visualization in GelOctober, 2008
Kyiv, 29th of October 2008 – OTAVA Ltd., a leading Ukrainian fluorescent probe company, and SIGMA-ALDRICH, world-wide known Life Science and High Technology company, jointly released novel fluorescent stain Nancy-520 for dsDNA visualization on agarose gels.
|
|
Read more...
|
Otava offer Protein Kinase inhibitors set ( KISTM) for kinase-associated research
December, 2008
OTAVA offers Protein Kinase inhibitors set (KISTM) for kinase-associated research. KISTM contains 17 known kinase inhibitors. A majority of these inhibitors are available from our company only.
|
|
Read more...
|
OTAVA sponsoring Protein Kinase Targets Conference
February, 2009
OTAVA Ltd. is a Corporate Sponsor of Protein Kinase Targets Conference (June 1-3, 2009, Royal Sonesta Hotel, Cambridge Massachusetts).
|
|
Read more...
|
|
|
HOME
Overview
On-line compound search
